This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

Biotech stocks can be risky but exciting investments because they can soar quickly on positive news, such as a drug approval or simply the hope that they may soon have an approved treatment. They can drop just as quickly on negative news. One stock that has recently skyrocketed is ProKidney (NASDAQ: PROK).At the start of the month, it was firmly in penny stock territory, with a price of less than $0.60. But as of the end of last week, it was up over $4.50, having taken off in value on some encouraging developments. And yet, even despite soaring well over 600% in less than a week, its market cap remains at around $2 billion as I write this. What's behind the healthcare stock's impressive rally, and should you consider investing in ProKidney today?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool